A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL- 2Rγnull mouse lymphoma model

Cancer Immunology, Immunotherapy

Volumn 59, Issue 12, 2010, Pages 1791-1800

  Sato, Fumihiko ^a   Ito, Asahi ^a   Ishida, Takashi ^a   Mori, Fumiko ^a   Takino, Hisashi ^a   Inagaki, Atsushi ^a   Ri, Masaki ^a   Kusumoto, Shigeru ^a   Komatsu, Hirokazu ^a   Iida, Shinsuke ^a   Okada, Noriko ^a   Inagaki, Hiroshi ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Antibody therapy; CDC; Humanized mouse

Indexed keywords

113F ANTIBODY; CD20 ANTIBODY; CD20 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; DECAY ACCELERATING FACTOR; INTERLEUKIN 2 RECEPTOR GAMMA; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COMPLEMENT; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SCID MOUSE; ANIMAL; CYTOTOXICITY; DISEASE MODEL; IMMUNOLOGY; LYMPHOMA, B-CELL; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77957679778     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0905-2     Document Type: Article

References (34)

1. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 1:CAS:528: DC%2BD38XmslGgsw%3D%3D 10.1056/NEJMoa011795 11807147 (Pubitemid 34438862)
2. M Pfreundschuh L Trümper A Osterborg R Pettengell M Trneny K Imrie D Ma D Gill J Walewski PL Zinzani R Stahel S Kvaloy O Shpilberg U Jaeger M Hansen T Lehtinen A López-Guillermo C Corrado A Scheliga N Milpied M Mendila M Rashford E Kuhnt M Loeffler 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 1:CAS:528: DC%2BD28XjvFWlsbw%3D 10.1016/S1470-2045(06)70664-7 16648042
3. G Cartron H Watier J Golay P Solal-Celigny 2004 From the bench to the bedside: ways to improve rituximab efficacy Blood 104 2635 2642 1:CAS:528:DC%2BD2cXpslKjs70%3D 10.1182/blood-2004-03-1110 15226177 (Pubitemid 39434941)
4. MR Smith 2003 Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 7359 7368 1:CAS:528:DC%2BD3sXotlajuro%3D 10.1038/sj.onc.1206939 14576843
5. MT Voso G Pantel S Rutella M Weis F D'Alò R Urbano G Leone R Haas S Hohaus 2002 Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms Haematologica 87 918 925 1:CAS:528:DC%2BD38XptVKnsrg%3D 12217803
6. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 443 446 1:CAS:528:DC%2BD3cXisVOru7Y%3D 10.1038/74704 10742152 (Pubitemid 30208162)
7. G Cartron L Dacheux G Salles P Solal-Celigny P Bardos P Colombat H Watier 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 754 758 1:CAS:528:DC%2BD38XhtVals7k%3D 10.1182/blood.V99.3.754 11806974 (Pubitemid 34525533)
8. R Bannerji S Kitada IW Flinn M Pearson D Young JC Reed JC Byrd 2003 Apoptotic-regulatory and complement protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance J Clin Oncol 21 1466 1471 1:CAS:528:DC%2BD2cXptlCks7Y%3D 10.1200/JCO.2003.06.012 12697868 (Pubitemid 46594097)
9. N Di Gaetano E Cittera R Nota A Vecchi V Grieco E Scanziani M Botto M Introna J Golay 2003 Complement activation determines the therapeutic activity of rituximab in vivo J Immunol 171 1581 1587 1:CAS:528:DC%2BD3sXlsFylu7g%3D 12874252
10. AD Kennedy PV Beum MD Solga DJ DiLillo MA Lindorfer CE Hess JJ Densmore ME Williams RP Taylor 2004 Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia J Immunol 172 3280 3288 1:CAS:528:DC%2BD2cXhsVCqsbs%3D 14978136
11. SP Treon C Mitsiades N Mitsiades G Young D Doss R Schlossman KC Anderson 2001 Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J Immunother 24 263 271 1:CAS:528:DC%2BD3MXksVyhs7w%3D 10.1097/00002371-200105000-00011 (Pubitemid 32479718)
12. O Manches G Lui L Chaperot R Gressin JP Molens MC Jacob JJ Sotto D Leroux JC Bensa J Plumas 2003 In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood 101 949 954 1:CAS:528:DC%2BD3sXptVeqtA%3D%3D 10.1182/blood-2002-02-0469 12393572 (Pubitemid 36139365)
13. MS Cragg MJ Glennie 2004 Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood 103 2738 2743 1:CAS:528: DC%2BD2cXjtVaksLc%3D 10.1182/blood-2003-06-2031 14551143 (Pubitemid 38393032)
14. J Golay M Lazzari V Facchinetti S Bernasconi G Borleri T Barbui A Rambaldi M Introna 2001 CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 3383 3389 1:CAS:528:DC%2BD3MXovVSgsb8%3D 10.1182/blood.V98.12.3383 11719378
15. A Hagenbeek O Gadeberg P Johnson LM Pedersen J Walewski A Hellmann BK Link T Robak M Wojtukiewicz M Pfreundschuh M Kneba A Engert P Sonneveld M Flensburg J Petersen N Losic J Radford 2008 First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 111 5486 5495 1:CAS:528:DC%2BD1cXnsVOkt78%3D 10.1182/blood-2007-10-117671 18390837
16. B Coiffier S Lepretre LM Pedersen O Gadeberg H Fredriksen MH van Oers J Wooldridge J Kloczko J Holowiecki A Hellmann J Walewski M Flensburg J Petersen T Robak 2008 Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood 111 1094 1100 1:CAS:528: DC%2BD1cXhvFejsbs%3D 10.1182/blood-2007-09-111781 18003886 (Pubitemid 351213387)
17. A Natsume M In H Takamura T Nakagawa Y Shimizu K Kitajima M Wakitani S Ohta M Satoh K Shitara R Niwa 2008 Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities Cancer Res 68 3863 3872 1:CAS:528:DC%2BD1cXlvVOiurk%3D 10.1158/0008-5472.CAN-07-6297 18483271
18. A Inagaki T Ishida H Yano T Ishii S Kusumoto A Ito M Ri F Mori J Ding H Komatsu S Iida R Ueda 2009 Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC Int J Cancer 125 212 221 1:CAS:528:DC%2BD1MXmslCgurY%3D 10.1002/ijc.24351 19358282
19. J Golay L Zaffaroni T Vaccari M Lazzari GM Borleri S Bernasconi F Tedesco A Rambaldi M Introna 2000 Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 3900 3908 1:CAS:528:DC%2BD3cXktFCht7o%3D 10845926
20. A Natsume Y Shimizu-Yokoyama M Satoh K Shitara R Niwa 2009 Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity Cancer Sci 100 2411 2418 1:CAS:528:DC%2BD1MXhsFOltrnK 10.1111/j.1349-7006.2009.01327.x 19758394
21. M Ito K Kobayashi T Nakahata 2008 NOD/Shi-scid IL2r-null (NOG) mice more appropriate for humanized mouse models Curr Top Microbiol Immunol 324 53 76 1:CAS:528:DC%2BD1cXosFGnsr0%3D 10.1007/978-3-540-75647-7-3 18481452
22. A Ito T Ishida A Utsunomiya F Sato F Mori H Yano A Inagaki S Suzuki H Takino M Ri S Kusumoto H Komatsu S Iida H Inagaki R Ueda 2009 Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo J Immunol 183 4782 4791 1:CAS:528:DC%2BD1MXhtFGjsL3L 10.4049/jimmunol.0900699 19748990
23. A Ito T Ishida H Yano A Inagaki S Suzuki F Sato H Takino F Mori M Ri S Kusumoto H Komatsu S Iida H Inagaki R Ueda 2009 Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model Cancer Immunol Immunother 58 1195 1206 1:CAS:528:DC%2BD1MXmsVGju7k%3D 10.1007/s00262-008-0632-0 19048251
24. T Ishida S Iida Y Akatsuka T Ishii M Miyazaki H Komatsu H Inagaki N Okada T Fujita K Shitara S Akinaga T Takahashi A Utsunomiya R Ueda 2004 The CC chemokine receptor 4 as a novel-specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma Clin Cancer Res 10 7529 7539 1:CAS:528: DC%2BD2cXhtVanur%2FP 10.1158/1078-0432.CCR-04-0983 15569983 (Pubitemid 39557514)
25. I Bergman PH Basse MA Barmada JA Griffin NK Cheung 2000 Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors Cancer Immunol Immunother 49 259 266 1:CAS:528:DC%2BD3cXlvFymt78%3D 10.1007/s002620000120 10941909
26. MJ Walport 2001 Complement: first of two parts N Engl J Med 344 1058 1066 1:CAS:528:DC%2BD3MXivFGnu7s%3D 10.1056/NEJM200104053441406 11287977 (Pubitemid 32267977)
27. MJ Walport 2001 Complement: second of two parts N Engl J Med 344 1140 1144 1:CAS:528:DC%2BD3MXjtFWgsbs%3D 10.1056/NEJM200104123441506 11297706 (Pubitemid 32285236)
28. T Ishida A Utsunomiya S Iida H Inagaki Y Takatsuka S Kusumoto G Takeuchi S Shimizu M Ito H Komatsu A Wakita T Eimoto K Matsushima R Ueda 2003 Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome Clin Cancer Res 9 3625 3634 1:CAS:528:DC%2BD3sXosVOlu7w%3D 14506150
29. VN Schumaker MA Calcott HL Spiegelberg HJ Muller-Eberhard 1976 Ultracentrifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement Biochemistry 15 5175 5181 1:CAS:528:DyaE2sXhsFWjug%3D%3D 10.1021/bi00668a035 990273
30. T Ishida R Ueda 2006 CCR4 as a novel molecular target for immunotherapy of cancer Cancer Sci 97 1139 1146 1:CAS:528:DC%2BD28XhtFemtbjJ 10.1111/j.1349-7006.2006.00307.x 16952304 (Pubitemid 44430638)
31. T Kubota R Niwa M Satoh S Akinaga K Shitara N Hanai 2009 Engineered therapeutic antibodies with improved effector functions Cancer Sci 100 1566 1572 1:CAS:528:DC%2BD1MXhtFOhurvN 10.1111/j.1349-7006.2009.01222.x 19538497
32. GA Lazar W Dang S Karki O Vafa JS Peng L Hyun C Chan HS Chung A Eivazi SC Yoder J Vielmetter DF Carmichael RJ Hayes BI Dahiyat 2006 Engineered antibody Fc variants with enhanced effector function Proc Natl Acad Sci USA 103 4005 4010 1:CAS:528:DC%2BD28XivFWitLw%3D 10.1073/pnas.0508123103 16537476
33. K Yamamoto A Utsunomiya K Tobinai K Tsukasaki N Uike K Uozumi K Yamaguchi Y Yamada S Hanada K Tamura S Nakamura H Inagaki K Ohshima H Kiyoi T Ishida K Matsushima S Akinaga M Ogura M Tomonaga R Ueda 2010 Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma J Clin Oncol 28 1591 1598 1:CAS:528:DC%2BC3cXltFGht7w%3D 10.1200/JCO.2009.25.3575 20177026
34. T Ishii T Ishida A Utsunomiya A Inagaki H Yano H Komatsu S Iida K Imada T Uchiyama S Akinaga K Shitara R Ueda 2010 Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma Clin Cancer Res 16 1520 1531 1:CAS:528:DC%2BC3cXisFSis7Y%3D 10.1158/1078-0432.CCR-09-2697 20160057